NAMS Relative Valuation
NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAMS is overvalued; if below, it's undervalued.
Historical Valuation
NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 141.88 is considered Fairly compared with the five-year average of 3.35. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 4.35 to 80.98 according to relative valuation methord.
Relative Value
Fair Zone
4.35-80.98
Current Price：21.44
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.03
P/B
Median3y
3.26
Median5y
0.41
-5.65
FCF Yield
Median3y
-6.00
Median5y
-6.00
Competitors Valuation Multiple
The average P/S ratio for NAMS's competitors is 38.35, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 141.88, which is 269.97% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is NewAmsterdam Pharma Company NV (NAMS) currently overvalued or undervalued?
What is NewAmsterdam Pharma Company NV (NAMS) fair value?
How does NAMS's valuation metrics compare to the industry average?
What is the current P/B ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?
What is the current FCF Yield for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?
What is the current Forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) as of Jul 18 2025?